Ticker LaunchReverse merger · Pending
Dr Ashleys Bio Labs Limited
Reverse merger with Impact BioMedical Inc. (IBO)
Dr Ashleys Bio Labs Limited agreed to merge into Impact BioMedical Inc. (IBO), a NYSE-listed pharmaceutical company combining with Dr Ashleys through a new Cayman holding company, in a reverse merger that takes the private company public. The deal was announced on Jun 21, 2025. The combined company is expected to trade as Dr Ashleys Limited on NYSE.
- Status
- Pending
- Private company
- Dr Ashleys Bio Labs Limited
- Public company
- Impact BioMedical Inc. (IBO)
- Public company business before
- NYSE-listed pharmaceutical company combining with Dr Ashleys through a new Cayman holding company
- Announced
- Jun 21, 2025
- Combined company
- Dr Ashleys Limited
- Exchange
- NYSE
- Sector
- Biotech & pharma
More on this deal for subscribers
- Ownership split between private and public holders
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- 8-K amendment to merger and share exchange agreement Mar 4, 2026
- DEF 14A (registration/proxy) Sep 22, 2025
- All filings on EDGAR CIK 1834105
Other pending reverse mergers
- Avenzo Therapeutics, Inc.into Rallybio Corporation · Jun 1, 2026
- Mentari Therapeutics, Inc.into InMed Pharmaceuticals Inc. · May 19, 2026
- Eos SENOLYTIX, Inc.into Pulmatrix, Inc. · Mar 26, 2026
- Gravitics, Inc.into Non-Invasive Monitoring Systems, Inc. · Mar 6, 2026
- Thramann Holdings, LT350, Influence Healthcare, Voyexinto Auddia Inc. · Feb 17, 2026
- Clywedog Therapeutics, Inc.into Barinthus Biotherapeutics plc · Sep 29, 2025